Sugi Predict

Sugi Predict / Compounds / Lifibrol

Lifibrol

Lifibrol

SCHEMBL140583

CC(C)(C)c1ccc(CCC(O)COc2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 2/20 0.64
▸ RXRA P19793 2/20 0.64
▸ RXRB P28702 2/20 0.64
▸ PLA2G4B P0C869 1/20 0.50
▸ EPHX2 P34913 3/20 0.48
▸ NR1H4 Q96RI1 3/20 0.48
▸ MAPT P10636 4/20 0.47
▸ LMNA P02545 3/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ RARB P10826 1/20 0.47
▸ RARG P13631 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SRD5A2 P31213 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.46
▸ NR4A1 P22736 1/20 0.46
▸ NR4A3 Q92570 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lifibrol SCHEMBL9484778 1.00 NR4A2 (0.64) NR4A2RXRARXRBPLA2G4BEPHX2
Lifibrol SCHEMBL9478310 1.00 NR4A2 (0.64) NR4A2RXRARXRBPLA2G4BEPHX2
SCHEMBL9736669 0.90 RXRA (0.51) NR4A2RXRARXRBPLA2G4BNR1H4
Terbufibrol SCHEMBL2733943 0.88 NR4A2 (0.67) NR4A2RXRARXRBPLA2G4BEPHX2
SCHEMBL10820832 0.88 CA1 (0.52) NR4A2RXRARXRBEPHX2NR1H4
SCHEMBL9485011 0.88 CA1 (0.52) NR4A2RXRARXRBEPHX2NR1H4
SCHEMBL10629599 0.87 NR1H4 (0.57) NR4A2RXRARXRBEPHX2NR1H4
SCHEMBL10820851 0.86 NR1H4 (0.58) NR4A2RXRARXRBEPHX2NR1H4
SCHEMBL8829626 0.85 RXRA (0.56) NR4A2RXRARXRBEPHX2NR1H4
SCHEMBL2654483 0.84 RXRA (0.60) NR4A2RXRARXRBEPHX2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 682 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11136342-B2 Carbonate prodrugs and methods of using the same ACORDA THERAPEUTICS, INC. (US) 2021-10-05 — — US claimed
US-20200157126-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME ACORDA THERAPEUTICS, INC. 2020-05-21 — — US claimed
CN-109893528-A Koumine treats the purposes of disorders of lipid metabolism and its related disease or illness 福建医科大学 2019-06-18 — — CN claimed
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents SATYAM APPARAO (IN) 2015-11-19 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
WO-2014111957-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS SATYAM APPARAO (IN) 2014-07-24 — — WO claimed
US-8541607-B2 Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof LACER, S.A. (ES) 2013-09-24 — — US claimed
US-8268352-B2 Modified release composition for highly soluble drugs TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-18 — — US claimed
US-8263125-B2 Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients TORRENT PHARMACEUTICALS LIMITED (IN) 2012-09-11 — — US claimed
JP-4809769-B2 — — 2011-11-09 — — JP claimed
CN-1045083-C Lifibrol and its use KLINGE CO CHEM PHARM FAB (DE) 1999-09-15 — — CN claimed
EP-0622351-B1 4-(4-(4'-tert.butylphenyl)-2-hydroxybutoxy)-benzoique acid and its utilization KLINGE CO CHEM PHARM FAB (DE) 1997-06-18 — — EP claimed
US-5493051-A ANTICHOLESTEROL AGENTS KLINGE PHARMA GMBH (DE) 1996-02-20 — — US claimed
WO-1995028924-A1 COMBINED PREPARATIONS CONTAINING A p-OXYBENZOIC ACID DERIVATIVE SUCH AS LIFIBROL AND AN HMG-CoA-REDUCTASE INHIBITOR SUCH AS LOVASTATIN, PRAVASTATIN OR SIMVASTATIN KLINGE PHARMA GMBH (DE) 1995-11-02 — — WO claimed
WO-1995028919-A1 MEDICAMENT CONTAINING p-OXYBENZOIC ACID DERIVATIVE AND FIBRATE KLINGE PHARMA GMBH (DE) 1995-11-02 — — WO claimed
EP-0518110-B1 Process for the preparation of pure enatiomers of 4-[4-(4'-tert.butylphenyl)-2-hydroxybutoxy]-benzoic acid and its alkyl ester KLINGE CO CHEM PHARM FAB (DE) 1995-08-09 — — EP claimed
CN-1104203-A Lifibrol and its use KLINGE CO CHEM PHARM FAB (DE) 1995-06-28 — — CN claimed
EP-0622351-A1 4-(4-(4'-tert.butylphenyl)-2-hydroxybutoxy)-benzoique acid and its utilization Klinge Pharma GmbH (DE) 1994-11-02 — — EP claimed
US-5266721-A Process for preparing the pure enantiomers of lifibrol and its alkyl esters KLINGE PHARMA GMBH (DE) 1993-11-30 — — US claimed
EP-0518110-A2 Process for the preparation of pure enatiomers of 4-[4-(4'-tert.butylphenyl)-2-hydroxybutoxy]-benzoic acid and its alkyl ester Klinge Pharma GmbH (DE) 1992-12-16 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157126-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME CA6, CA7, CA4 NR4A2 1564/4885RXRA 3248/4885RXRB 3380/4885
US-11136342-B2 Carbonate prodrugs and methods of using the same CA6, CA7, CA4 NR4A2 1564/4885RXRA 3248/4885RXRB 3380/4885
US-20150328323-A1 Nitric Oxide Releasing Produgs of Therapeutic Agents NOS2, NOS1, PTGIS NR4A2 2172/4885RXRA 2598/4885RXRB 2792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.